Eton Pharmaceuticals appoints Gruber as CFO

DEER PARK - Eton Pharmaceuticals Inc. said it has appointed James Gruber as chief financial officer, effective immediately. He succeeds Wilson Troutman, who is retiring.

Troutman will remain with the company through the end of May to ensure a smooth transition.

Gruber brings more than 20 years of financial and accounting experience to Eton. Most recently, he was the U.S. controller at Horizon Therapeutics for seven years, where he oversaw accounting activities for the company during its rapid growth. During Gruber's tenure at Horizon, the company closed and integrated multiple acquisitions, launched new products, and saw its revenue increase more than 10-fold.

Prior to Horizon, Gruber spent 14 years at Abbott Laboratories where he held various financial and accounting leadership positions. He holds an M.B.A. from Northwestern University's Kellogg School of Management, a bachelor's degree in accounting from Indiana University, and is a Certified Public Accountant.

"On behalf of everyone at Eton, I want to thank Wilson for his dedicated service to the company and congratulate him on a well-deserved retirement," said Sean Brynjelsen, CEO of Eton Pharmaceuticals. "Wilson has been instrumental to the company since its inception in 2017. His contributions to the company were both positive and impactful over the years."